Bank of Montreal Boosts Vertex Pharmaceuticals Holdings by 15.5%

The Canadian bank now owns over 419,000 shares of the biotech firm.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Bank of Montreal Can, a major Canadian financial institution, increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.5% in the third quarter of 2025, according to a recent SEC filing. The bank now owns 419,458 shares of the pharmaceutical company's stock, valued at approximately $164.28 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. The increased investment by a major institutional investor like Bank of Montreal Can suggests confidence in the company's future prospects and pipeline.

The details

In its latest 13F filing, Bank of Montreal Can reported that it had grown its position in Vertex Pharmaceuticals by adding 56,423 additional shares during the third quarter. This increased the bank's total stake in the company to 419,458 shares, or approximately 0.17% of Vertex's outstanding stock.

  • Bank of Montreal Can filed its 13F report for the third quarter of 2025 on March 11, 2026.

The players

Bank of Montreal Can

A major Canadian financial institution and one of the largest banks in North America.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Bank of Montreal Can in Vertex Pharmaceuticals underscores the biotech firm's strong position in the pharmaceutical industry and the confidence institutional investors have in its future growth prospects.